NCT07154706 2026-04-14
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
Phase 3 Recruiting
Clinical Trials
4 trialsNCT06564324 2026-04-13
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.
Phase 3 Recruiting
NCT04919811 2026-01-07
TRUST-II
Nuvation Bio Inc.
Phase 2 Active not recruiting
NCT06214793 2025-05-01
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Case Comprehensive Cancer Center
Phase 2 Suspended